// App-Quantinova.ai

9050 : Antitumor activity of ASP8273 300 mg in subjects with EGFR mutation-positive non-small cell lung cancer: Interim results from an ongoing phase 1 study.

Researchers

Presenter

  • Helena Alexandra Yu

Principal Investigators

  • Alexander I. Spira

  • Leora Horn

  • Jared Weiss

  • Howard Jack West

  • Giuseppe Giaccone

  • Tracey L. Evans

  • Ronan Joseph Kelly

  • Bhardwaj B. Desai

  • Andrew Krivoshik

  • Tanya E. Fleege

  • Srinivasu Poondru

  • Fei Jie

  • Kouji Aoyama

  • Debbie Ann Whitcomb

  • Anne Therese Keating

  • Geoffrey R. Oxnard

Medical Centers

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Virginia Cancer Specialists Research Institute, and Oncology Research, Fairfax, VA

  • Vanderbilt University Medical Center, Nashville, TN

  • Lineberger Comprehensive Cancer Center at the University of North Carolina, Chapel Hill, NC

  • Swedish Cancer Institute, Seattle, WA

  • Georgetown University, Washington, DC

  • University of Pennsylvania, Philadelphia, PA

  • The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD

  • Astellas Pharma, Inc., Northbrook, IL

  • Astellas Pharma, Inc, Tokyo, Japan

  • Dana-Farber Cancer Institute, Boston, MA

Locations

  • United States

  • Japan

Companies

  • Astellas Pharma US,

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Non Small Cell Lung cancer

Biomarkers

  • Epidermal growth factor receptor

  • Threonine at amino acid position 790

Drug/Treatment

  • ASP-8273

Outcome

  • Unknown

Study Design

  • Dose Escalation

  • Cohort

Phase

  • I

Study Id's

  • NCT02113813

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved